1.        Henry D A. Hyponatremia[J]. Annals of Internal Medicine, 2015, 163(3): ITC1-ITC1.

2.        Frederik H Verbrugge, Paul Steels, Lars Grieten, et al. Hyponatremia in acute decompensated heart failure: depletion versus dilution[J]. J Am Coll Cardiol, 2015, 65(5): 480-492.

3.        Amine Benmassaoud, Suzanne C Freeman, Davide Roccarina, et al. Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis[J]. Cochrane Database Syst Rev, 2020, 1:CD013123.

4.        D'Amico G, Pasta L, Morabito A, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients[J]. Aliment Pharmacol Ther, 2014, 39(10): 1180-1193.

5.        Pere Gines, Monica Guevara. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management[J]. Hepatology, 2008, 48(3): 1002-1010.

6.        Mark Sherlock, Eoin O'Sullivan, Amar Agha, et al. The incidence and pathophysiology of hyponatraemia after subarachnoid haemorrhage[J]. Clin Endocrinol (Oxf), 2006, 64(3): 250-254.

7.        Maria Carlota Londono, Monica Guevara, Antoni Rimola, et al. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation[J]. Gastroenterology, 2006, 130(4): 1135-1143.

8.        Robert Schrier, Arroyo V, Mauro Bernardi, et al. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis[J]. Hepatology, 1988, 8(5): 1151-1157.

9.        Laura Turco, Guadalupe Garcia-Tsao. Portal hypertension: pathogenesis and diagnosis[J]. Clin Liver Dis, 2019, 23(4): 573-587.

10.      Piano S, Tonon M, Angeli P. Management of ascites and hepatorenal syndrome[J]. Hepatol Int, 2018, 12(Suppl 1):122-134.

11.      Adebayo D, Neong S F, Wong F. Ascites and hepatorenal syndrome[J]. Clin Liver Dis, 2019, 23(4): 659-682.

12.      Florian Lang, Christoph Bohmer, Monica Palmada, et al. (Patho)physiological significance of the serum- and glucocorticoid-inducible kinase isoforms[J]. Physiol Rev, 2006, 86(4): 1151-1178.

13.      David Pearce, Rama Soundararajan, Christiane Trimpert, et al. Collecting duct principal cell transport processes and their regulation[J]. Clin J Am Soc Nephrol, 2015, 10(1): 135-146.

14.      Juan Pablo Arroyo, Dagmara Lagnaz, Caroline Ronzaud, et al. Nedd4-2 modulates renal Na+-Cl- cotransporter via the aldosterone-SGK1-Nedd4-2 pathway[J]. J Am Soc Nephrol, 2011, 22(9): 1707-1719.

15.      DuVall M D, Zhu Sheng-he, Fuller C M, et al. Peroxynitrite inhibits amiloride-sensitive Na+ currents inXenopus oocytes expressing αβγ-rENaC[J]. American J Physiology-Cell Physiology, 1998, 274(5): C1417-C1423.

16.      My N Helms, Yu Ling, Bela Malik, et al. Role of SGK1 in nitric oxide inhibition of ENaC in Na+-transporting epithelia[J]. Am J Physiol Cell Physiol, 2005, 289(3): C717-726.

17.      Yang Lei, Gustavo Frindt, Florian Lang, et al. SGK1-dependent ENaC processing and trafficking in mice with high dietary K intake and elevated aldosterone[J]. Am J Physiol Renal Physiol, 2017, 312(1): F65-F76.

18.      Al-Qusairi Lama, Basquin Denis, Roy Ankita, et al. Renal tubular SGK1 deficiency causes impaired K+ excretion via loss of regulation of NEDD4-2/WNK1 and ENaC[J]. Am J Physiol Renal Physiol, 2016, 311(2): F330-342.

19.      Fenja Knoepp, Zoe Ashley, Daniel Barth, et al. Shear force sensing of epithelial Na(+) channel (ENaC) relies on N-glycosylated asparagines in the palm and knuckle domains of alphaENaC[J]. Proc Natl Acad Sci U S A, 2020, 117(1): 717-726.

20.      Verney E B. Absorption and excretion of water the antidiuretic hormone[J]. The Lancet, 1946, 248(6430): 739-744.

21.      Antoni F A. Vasopressin as a stress hormone[M]. Stress: Neuroendocrinology and Neurobiology, 2017: 97-108.

22.      Eric Féraille, Alain Doucet. Sodium-potassium-adenosinetriphosphatase-dependent sodium transport in the kidney: hormonal control [J]. Physiological Reviews, 2001, 81(1): 345-418.

23.      Detlef Bockenhauer, Daniel-G Bichet. Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus[J]. Nat Rev Nephrol, 2015, 11(10): 576-588.

24.      Saif A Muhsin, David Mount. Diagnosis and treatment of hypernatremia[J]. Best Pract Res Clin Endocrinol Metab, 2016, 30(2): 189-203.

25.      Tanja Vukicevic, Maike Schulz, Dorte Faust, et al. The trafficking of the water channel Aquaporin-2 in renal principal cells-a potential target for pharmacological intervention in cardiovascular diseases [J]. Front Pharmacol, 2016, 7(62): 23.

26.      Wang W-L, Su S-H, Wong K Y, et al. Rab7 involves Vps35 to mediate AQP2 sorting and apical trafficking in the collecting duct cells[J]. American J Physiology-Renal Physiology, 2020.

27.      Enno Klussmann, Grazia Tamma, Dorothea Lorenz, et al. An inhibitory role of Rho in the vasopressin-mediated translocation of Aquaporin-2 into cell membranes of renal principal cells [J]. J Biological Chemistry, 2001, 276(23): 20451-20457.

28.      Katharina Schrade, Jessica Tröger, Adeeb Eldahshan, et al. An AKAP-Lbc-RhoA interaction inhibitor promotes the translocation of aquaporin-2 to the plasma membrane of renal collecting duct principal cells[J]. PLOS ONE, 2018, 13(1): e0191423.

29.      Tanja Vukicevic, Christian Hinze, Sandrine Baltzer, et al. Fluconazole increases osmotic water transport in renal collecting duct through effects on Aquaporin-2 trafficking [J]. J Am Soc Nephrol, 2019, 30(5): 795-810.

30.      Luo Ren-fei, Hu Shan, Liu Qiao-juan, et al. Hydrogen sulfide upregulates renal AQP-2 protein expression and promotes urine concentration[J]. FASEB J, 2019, 33(1): 469-483.

31.      Fumiaki Ando, Eisei Sohara, Tetsuji Morimoto, et al. Wnt5a induces renal AQP2 expression by activating calcineurin signalling pathway[J]. Nat Commun, 2016, 7: 13636.

32.      Birnbaumer M. Vasopressin receptors[J]. Trends in Endocrinology & Metabolism, 2000, 11(10): 406-410.

33.      Lise Bankir, Daniel-G Bichet, Nils G Morgenthaler. Vasopressin: physiology, assessment and osmosensation[J]. J Intern Med, 2017, 282(4): 284-297.

34.      Eric Feraille, Eva Dizin. Coordinated control of ENaC and Na+, K+-ATPase in renal collecting duct[J]. J Am Soc Nephrol, 2016, 27(9): 2554-2563.

35.      Ishibashi K, Sasaki S, Fushimi K, et al. Immunolocalization and effect of dehydration on AQP3, a basolateral water channel of kidney collecting ducts[J]. Am J Physiol, 1997, 272(2 Pt 2): F235-241.

36.      Soo Wan Kim, Veronika Gresz, Aleksandra Rojek, et al. Decreased expression of AQP2 and AQP4 water channels and Na,K-ATPase in kidney collecting duct in AQP3 null mice[J]. Biol Cell, 2005, 97(10): 765-778.

37.      Marika Rudler, Maxime Mallet, Pilippe Sultanik, et al. Optimal management of ascites[J]. Liver Int, 2020, 40 (Suppl 1):128-135.

38.      Chinese Society of Hepatology, Chinese Medical Association, Xu Xiao-yuan, et al. Chinese guidelines on the management of ascites and its related complications in cirrhosis[J]. Hepatol Int, 2019, 13(1): 1-21.

39.      Rossana Berardi, Candida Mastroianni, Giuseppe Lo Russo, et al. Syndrome of inappropriate anti-diuretic hormone secretion in cancer patients: results of the first multicenter Italian study[J]. Ther Adv Med Oncol, 2019, 11:1758835919877725.

40.      Reem A Mustafa, Alan S L Yu. Burden of Proof for Tolvaptan in ADPKD: Did REPRISE Provide the Answer?[J]. Clin J Am Soc Nephrol, 2018, 13(7):1107-1109.

41.      Annarita Di Mise, Maria Venneri, Marianna Ranieri, et al. Lixivaptan, a new generation diuretic, counteracts vasopressin-induced aquaporin-2 trafficking and function in renal collecting duct cells [J]. Int J Mol Sci, 2019, 21(1).

42.      Elsa Sola, Cristina Sole, Macarena Simon-Talero, et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial[J]. J Hepatol, 2018, 69(6): 1250-1259.

43.      Paolo Caraceni, Oliviero Riggio, Paolo Angeli, et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial[J]. The Lancet, 2018, 391(10138): 2417-2429.

44.      Cary H Paine, Raimund H Pichler. Treatment of hyponatremia in end-stage liver disease: new tools in the shed [J]. Am J Gastroenterol, 2018, 113(11):1728-1729.

45.      Mauro Bernardi, Paolo Caraceni, Roberta J Navickis, et al. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials[J]. Hepatology, 2012, 55(4): 1172-1181.

46.      Rezwan Ahmed, Prasanna Santhanam, Yaser Rayyan. MELD-Na as a prognostic indicator of 30- and 90-day mortality in patients with end-stage liver disease after creation of transjugular intrahepatic portosystemic shunt[J]. Eur J Gastroenterol Hepatol, 2015, 27(10): 1226-1227.

47.      Bryan Oronsky, Scott Caroen, Arnold Oronsky, et al. Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management[J]. Cancer Chemotherapy and Pharmacology, 2017, 80(5): 895-907.

48.      San-E Ishikawa. Is exaggerated release of arginine vasopressin an endocrine disorder? Pathophysiology and treatment [J]. J Clin Med, 2017, 6(11): 102.

49.      N Winn Seay, Ruediger W Lehrich, Arthur Greenberg. Diagnosis and management of disorders of body tonicity-hyponatremia and hypernatremia: core curriculum 2020 [J]. Am J Kidney Dis, 2020, 75(2): 272-286.

50.      Mirjam Christ-Crain. Vasopressin and Copeptin in health and disease[J]. Rev Endocr Metab Disord, 2019, 20(3): 283-294.

51.      Yamashita T, Yoshida M, Yamada H, et al. Prompt efficacy of tolvaptan in treating hyponatremia of syndrome of inappropriate secretion of antidiuretic hormone (SIADH) closely associated with rupture of a gastric artery aneurysm[J]. Intern Med, 2014, 53(8): 845-849.

52.      Zhao Ning, Stephanie O Peacock, Chen Hao Lo, et al. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer[J]. Science Translational Medicine, 2019, 11(498): eaaw4636.

53.      Taka-Aki Koshimizu, Aki Kashiwazaki, Junichi Taniguchi. Combined sodium ion sensitivity in agonist binding and internalization of vasopressin V1b receptors[J]. Sci Rep, 2016, 6: 25327.

54.      Kozo Hamada, Katsuhiko Mikoshiba. IP3 receptor plasticity underlying diverse functions [J]. Annu Rev Physiol, 2020, 82(1): 151-176.

55.      Andrea Kleindienst, Mark J Hannon, Michael Buchfelder, et al. Hyponatremia in neurotrauma: the role of vasopressin [J]. J Neurotrauma, 2016, 33(7): 615-624.

56.     Kazuaki Nakamura, Gilberto Velho, Nadine Bouby. Vasopressin and metabolic disorders: translation from experimental models to clinical use[J]. J Intern Med, 2017, 282(4): 298-309.

57.      Lynnette R Montgomery, Charles H Hubscher. Altered vasopressin and natriuretic peptide levels in a rat model of spinal cord injury: implications for the development of polyuria[J]. Am J Physiol Renal Physiol, 2018, 314(1): F58-F66.

58.      Liu Chao, Chen Ying, Kang Yun-xiao, et al. Glucocorticoids improve renal responsiveness to atrial natriuretic peptide by up-regulating natriuretic peptide receptor-A expression in the renal inner medullary collecting duct in decompensated heart failure[J]. J Pharmacol Exp Ther, 2011, 339(1): 203-209.

59.      Deborah P Jones. Syndrome of Inappropriate Secretion of Antidiuretic Hormone and Hyponatremia[J]. Pediatrics in Review, 2018, 39(1):27-35.

60.      Paul Grant, John Ayuk, Pierre-Marc Bouloux, et al. The diagnosis and management of inpatient hyponatraemia and SIADH[J]. Eur J Clin Invest, 2015, 45(8): 888-894.

61.      Guy Decaux, Fabrice Gankam Kengne, Couturier B, et al. Actual therapeutic indication of an old drug: urea for treatment of severely symptomatic and mild chronic hyponatremia related to SIADH[J]. J Clin Med, 2014, 3(3): 1043-1049.

62.      Helbert Rondon-Berrios, Srijan Tandukar, Mor Maria K, et al. Urea for the treatment of hyponatremia[J]. Clin J Am Soc Nephrol, 2018, 13(11): 1627-1632.

63.      Alain Soupart, Michel Coffernils, Couturier B, et al. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH[J]. Clin J Am Soc Nephrol, 2012, 7(5): 742-747.

64.      Andrew P Ambrosy, Gregg C Fonarow, Javed Butler, et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries[J]. J Am Coll Cardiol, 2014, 63(12):1123-1133.

65.      Zhang Ying-ying, Johann Bauersachs, Harald F Langer. Immune mechanisms in heart failure[J]. Eur J Heart Fail, 2017, 19(11): 1379-1389.

66.      Leonardo De Luca, Liviu Klein, James E Udelson, et al. Hyponatremia in patients with heart failure[J]. Am J Cardiol, 2005, 96(12A): 19L-23L.

67.      Luigi Adamo, Cibele Rocha-Resende, Sumanth D Prabhu, et al. Reappraising the role of inflammation in heart failure[J]. Nat Rev Cardiol, 2020, 17: 269-285.

68.      Yamashita Tomoya, Hayashi T, Yoshida N, et al. Gut microbial dysbiosis in heart failure- is it a future therapeutic target or not?[J]. Circ J, 2018, 82(6): 1507-1509.

69.      Mark Luedde, Thorben Winkler, Femke-Anouska Heinsen, et al. Heart failure is associated with depletion of core intestinal microbiota[J]. ESC Heart Fail, 2017, 4(3): 282-290.

70.      Takehiro Kamo, Hiroshi Akazawa, Wataru Suda, et al. Dysbiosis and compositional alterations with aging in the gut microbiota of patients with heart failure[J]. PLoS One, 2017,12(3): e0174099.

71.      Robert W Schrier. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone[J]. Am J Med, 2006, 119(7 Suppl 1): S47-53.

72.      Steven R Goldsmith, Mihai Gheorghiade. Vasopressin antagonism in heart failure[J]. J Am Coll Cardiol, 2005, 46(10): 1785-1791.

73.      Caterina Urso, Salvatore Brucculeri, Gregorio Caimi. Acid-base and electrolyte abnormalities in heart failure: pathophysiology and implications[J]. Heart Fail Rev, 2015, 20(4): 493-503.

74.      Christophe Heymes, Jennifer K Bendall, Philippe Ratajczak, et al. Increased myocardial NADPH oxidase activity in human heart failure[J]. J Am Coll Cardiol, 2003, 41(12): 2164-2171.

75.      De Vecchis R, Esposito C, Ariano C, et al. Hypertonic saline plus i.v. furosemide improve renal safety profile and clinical outcomes in acute decompensated heart failure: A meta-analysis of the literature[J]. Herz, 2015, 40(3): 423-435.

76.      Renato De Vecchis, Claudio Cantatrione, Damiana Mazzei, et al. Vasopressin receptor antagonists for the correction of hyponatremia in chronic heart failure: an underutilized therapeutic option in current clinical practice?[J]. J Clin Med, 2016, 5(10):86.

77.      Thomas A Zelniker, Eugene Braunwald. Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review [J]. J Am Coll Cardiol, 2020, 75(4):435-447.

78.      Austin Hsu, Duan Qi-ming, Sarah McMahon, et al. Salt-inducible kinase 1 maintains HDAC7 stability to promote pathologic cardiac remodeling[J]. J Clin Invest, 2020, 130(18), 10.1172/JCI133753.

79.      Takuro Numaga-Tomita, Motohiro Nishida. TRPC channels in cardiac plasticity[J]. Cells, 2020, 9(2), DOI: 10.3390/cells9020454.

80.      Steven R Goldsmith, James E Udelson, Mihai Gheorghiade. Dual vasopressin V1a/V2 antagonism: the next step in neurohormonal modulation in patients with heart failure?[J]. J Card Fail, 2018, 24(2): 112-114.

81.      Nathan A Pinner, Carrie Oliphant, Jack P Hopkins. Use of conivaptan for the treatment of symptomatic hyponatremia in a patient with acute decompensated heart failure[J]. Am J Health Syst Pharm, 2010, 67(12): 1011-1015.

82.      Robert A Fenton, Anneliese Flynn, Adetola Shodeinde, et al. Renal phenotype of UT-A urea transporter knockout mice[J]. J Am Soc Nephrol, 2005, 16(6): 1583-1592.

83.      Jiang Tao, Li Ying-jie, Antia T Layton, et al. Generation and phenotypic analysis of mice lacking all urea transporters[J]. Kidney Int, 2017, 91(2): 338-351.

84.      Ren Hui-wen, Wang Yan-hua, Xing Yong-ning, et al. Thienoquinolins exert diuresis by strongly inhibiting UT-A urea transporters[J]. Am J Physiol Renal Physiol, 2014, 307(12): F1363-1372.

85.      Li Min, Zhao Yan, Zhang Shun, et al. A thienopyridine, CB-20, exerts diuretic activity by inhibiting urea transporters[J]. Acta Pharmacol Sin, 2020, 41(1): 65-72.

86.      Marc O Anderson, Zhang Ji-cheng, Liu Yan, et al. Nanomolar potency and metabolically stable inhibitors of kidney urea transporter UT-B[J]. J Med Chem, 2012, 55(12): 5942-5950.

87.      Lee Su-jin, Onur Cil, Elena Diez-Cecilia, et al. Nanomolar-potency 1,2,4-triazoloquinoxaline inhibitors of the kidney urea transporter UT-A1[J]. J Med Chem, 2018, 61(7): 3209-3217.

88.      Onur Cil, Cristina Esteva-Font, Sadik Taskin Tas, et al. Salt-sparing diuretic action of a water-soluble urea analog inhibitor of urea transporters UT-A and UT-B in rats[J]. Kidney Int, 2015, 88(2): 311-320.